Evolus, Inc. (EOLS): Price and Financial Metrics
EOLS Price/Volume Stats
| Current price | $8.99 | 52-week high | $11.49 |
| Prev. close | $9.19 | 52-week low | $6.51 |
| Day low | $8.95 | Volume | 237,800 |
| Day high | $9.18 | Avg. volume | 556,557 |
| 50-day MA | $9.26 | Dividend yield | N/A |
| 200-day MA | $8.73 | Market Cap | 512.18M |
EOLS Stock Price Chart Interactive Chart >
EOLS POWR Grades
- EOLS scores best on the Growth dimension, with a Growth rank ahead of 90.2% of US stocks.
- EOLS's strongest trending metric is Stability; it's been moving down over the last 177 days.
- EOLS's current lowest rank is in the Stability metric (where it is better than 8.53% of US stocks).
EOLS Stock Summary
- EVOLUS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 0.93% of US listed stocks.
- EOLS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 95.46% of US stocks.
- With a year-over-year growth in debt of 29.81%, EVOLUS INC's debt growth rate surpasses 79.5% of about US stocks.
- If you're looking for stocks that are quantitatively similar to EVOLUS INC, a group of peers worth examining would be DTC, TOMZ, SND, LOB, and AX.
- EOLS's SEC filings can be seen here. And to visit EVOLUS INC's official web site, go to www.evolus.com.
EOLS Valuation Summary
- EOLS's price/sales ratio is 3.1; this is 63.16% higher than that of the median Healthcare stock.
- EOLS's EV/EBIT ratio has moved up 30.3 over the prior 68 months.
Below are key valuation metrics over time for EOLS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EOLS | 2023-09-22 | 3.1 | -75.2 | -7.9 | -10.5 |
| EOLS | 2023-09-21 | 3.1 | -74.9 | -7.9 | -10.4 |
| EOLS | 2023-09-20 | 3.1 | -75.2 | -7.9 | -10.5 |
| EOLS | 2023-09-19 | 3.1 | -74.5 | -7.8 | -10.4 |
| EOLS | 2023-09-18 | 3.2 | -76.7 | -8.1 | -10.7 |
| EOLS | 2023-09-15 | 3.2 | -77.2 | -8.1 | -10.7 |
EOLS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EOLS has a Quality Grade of C, ranking ahead of 44.26% of graded US stocks.
- EOLS's asset turnover comes in at 0.373 -- ranking 125th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows EOLS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.373 | 0.630 | -3.772 |
| 2021-03-31 | 0.300 | 0.674 | -1.580 |
| 2020-12-31 | 0.271 | 0.676 | -1.214 |
| 2020-09-30 | 0.256 | 0.735 | -0.356 |
| 2020-06-30 | 0.245 | 0.734 | -0.491 |
| 2020-03-31 | 0.216 | 0.731 | -0.603 |
EOLS Price Target
For more insight on analysts targets of EOLS, see our EOLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.14 | Average Broker Recommendation | 1.57 (Moderate Buy) |
Evolus, Inc. (EOLS) Company Bio
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California.
Latest EOLS News From Around the Web
Below are the latest news stories about EVOLUS INC that investors may wish to consider to help them evaluate EOLS as an investment opportunity.
7 Small-Cap Stocks Analysts Predict Will Double in 2024While small-cap stocks to buy present exceptional risk, they also offer tremendous rewards for intrepid retail investors. |
Insider Sell: CFO Sandra Beaver Sells 3,178 Shares of Evolus Inc (EOLS)On September 6, 2023, Sandra Beaver, the Chief Financial Officer (CFO) of Evolus Inc (NASDAQ:EOLS), sold 3,178 shares of the company. |
Evolus, Inc. (NASDAQ:EOLS) is a favorite amongst institutional investors who own 56%Key Insights Significantly high institutional ownership implies Evolus' stock price is sensitive to their trading... |
12 Cheapest and Best Countries for Plastic SurgeryIn this article, we will look at the 12 cheapest and best countries for plastic surgery. If you want to skip our detailed analysis, head straight to the 5 Cheapest and Best Countries for Plastic Surgery. The global cosmetic surgery market, valued at $55.68 billion in 2022, is witnessing robust growth and is projected to […] |
Evolus to Participate in September ConferencesNEWPORT BEACH, Calif., August 29, 2023--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in two investment conferences in September. |
EOLS Price Returns
| 1-mo | -0.77% |
| 3-mo | 22.48% |
| 6-mo | 7.66% |
| 1-year | 11.40% |
| 3-year | 132.90% |
| 5-year | -49.61% |
| YTD | 19.71% |
| 2022 | 15.36% |
| 2021 | 93.75% |
| 2020 | -72.39% |
| 2019 | 2.27% |
| 2018 | N/A |
Continue Researching EOLS
Want to see what other sources are saying about Evolus Inc's financials and stock price? Try the links below:Evolus Inc (EOLS) Stock Price | Nasdaq
Evolus Inc (EOLS) Stock Quote, History and News - Yahoo Finance
Evolus Inc (EOLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...